EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BKI-1748 confers a high level of protection against ovine congenital toxoplasmosis when administered after IgM seroconversion

Roberto Sánchez-Sánchez, Natalia Velasco-Jiménez, David Arranz-Solís, Miguel Criado, Ignacio Ferre, Michela Re, Matthew A Hulverson, Ryan Choi, Lynn K Barrett, Andrew Hemphill, Wesley C Van Voorhis, Luis Miguel Ortega-Mora

Frontiers in Cellular and Infection Microbiology · 2026

DOI: 10.3389/fcimb.2026.1819490 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Roberto Sánchez-Sánchez und 11 weiteren Autor:innen. Beteiligte Einrichtung: SALUVET, Animal Health Department, Faculty of Veterinary Sciences, Complutense University of Madrid, Ciudad Universitaria s/n, Madrid, Spain. Hauptthemen laut MEDLINE: Immunoglobulin M, Antibodies, Protozoan, Toxoplasmosis, Animal, Toxoplasmosis, Congenital. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Agriculture, National Institutes of Health, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Unlike mouse models of congenital toxoplasmosis, pregnant sheep models provide the opportunity to evaluate treatment strategies that more closely resemble clinical practice in pregnant women, including chemotherapeutic interventions initiated after specific IgM seroconversion. BKI-1748, which targets Toxoplasma gondii CDPK1 and MAPKL-1 protein kinases, has demonstrated an excellent safety profile and efficacy when administered repeatedly to pregnant sheep, starting at 2 and 7 days after challenge.

Methods

In this study, treatment was initiated at day 14 post-infection (p.i.), following T. gondii IgM seroconversion. Twenty-three sheep were orally inoculated with 10 TgShSp1 oocysts at 90 days of gestation, while three sheep remained uninfected. On day 14 p.i., infected sheep carrying live fetuses (n = 10) received 10 doses of BKI-1748 orally at 15 mg/kg every 2 days, whereas 10 infected sheep were left untreated.

Results

All infected sheep, both treated and untreated, seroconverted to serum IgG by day 21 p.i., with treated sheep showing a marked reduction in IgG levels from day 28 p.i. onward. Administration of the compound significantly enhanced lamb viability in infected sheep, resulting in 91% viable lambs in treated animals compared to 52% in untreated sheep. Whereas all lambs born to untreated sheep were congenitally infected, only 17% of lambs in the treated group were infected. Nevertheless, congenitally infected lambs in the treated group had lower birth weights than T. gondii -free lambs.

Conclusion

This study highlights the potential utility of BKI-1748 for prenatal treatment of human congenital toxoplasmosis, in which IgM seroconversion prompts the need for intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin MAntibodies, ProtozoanToxoplasmosis, AnimalToxoplasmosis, CongenitalToxoplasmaSheep DiseasesAnimalsFemaleSheepPregnancySeroconversionDisease Models, AnimalImmunoglobulin G

Stichwörter der Autor:innen

BKI-1748IgMToxoplasma gondiicongenital toxoplasmosisefficacysheeptranslational pharmaceutics

Substanzen

Immunoglobulin MAntibodies, ProtozoanImmunoglobulin G

Autor:innen und Institutionen

  • SALUVET, Animal Health Department, Faculty of Veterinary Sciences, Complutense University of Madrid, Ciudad Universitaria s/n, Madrid, Spain.
  • Instituto de Ganadería de Montaña, (CSIC-ULE), Grulleros, León, Spain.
  • Animal Medicine and Surgery Department, Faculty of Veterinary Sciences, Complutense University of Madrid, Madrid, Spain.
  • Center for Emerging and Re-emerging Infectious Diseases (CERID), Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, United States.
  • Institute of Parasitology, Vetsuisse Faculty, University of Berne, Berne, Switzerland.

Förderung

  • U.S. Department of Agriculture
  • National Institutes of Health
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
  • Comunidad de Madrid

Zitieren

APA

Sánchez-Sánchez, R., Velasco-Jiménez, N., Arranz-Solís, D., Criado, M., Ferre, I., Re, M., Hulverson, M. A., Choi, R., Barrett, L. K., Hemphill, A., Van Voorhis, W. C., & Ortega-Mora, L. M. (2026). BKI-1748 confers a high level of protection against ovine congenital toxoplasmosis when administered after IgM seroconversion. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2026.1819490

Vancouver

Sánchez-Sánchez R, Velasco-Jiménez N, Arranz-Solís D, Criado M, Ferre I, Re M, et al. BKI-1748 confers a high level of protection against ovine congenital toxoplasmosis when administered after IgM seroconversion. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2026.1819490

BibTeX
@article{SnchezSnchez2026,
  author = {Sánchez-Sánchez, Roberto and Velasco-Jiménez, Natalia and Arranz-Solís, David and Criado, Miguel and Ferre, Ignacio and Re, Michela and Hulverson, Matthew A and Choi, Ryan and Barrett, Lynn K and Hemphill, Andrew and Van Voorhis, Wesley C and Ortega-Mora, Luis Miguel},
  title = {BKI-1748 confers a high level of protection against ovine congenital toxoplasmosis when administered after IgM seroconversion},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  doi = {10.3389/fcimb.2026.1819490}
}
Kostenlos starten →